Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
Femasys (NASDAQ: FEMY) announces a partnership with HRC Fertility, a major fertility services provider in the Western U.S., to offer FemaSeed Intratubal Insemination treatment at California locations. FemaSeed is a first-line fertility treatment that delivers sperm directly into the fallopian tube, showing higher efficacy compared to traditional intrauterine insemination for low male sperm count. The treatment offers a cost-effective option before pursuing IVF and ICSI procedures.
Femasys (NASDAQ: FEMY) annuncia una partnership con HRC Fertility, un importante fornitore di servizi per la fertilità negli Stati Uniti occidentali, per offrire il trattamento di Inseminazione Intratubale FemaSeed presso le sedi in California. FemaSeed è un trattamento di fertilità di prima linea che somministra lo sperma direttamente nella tuba di Falloppio, mostrando una maggiore efficacia rispetto all'inseminazione intrauterina tradizionale per bassi conteggi di spermatozoi maschili. Il trattamento offre un'opzione economica prima di considerare procedure di IVF e ICSI.
Femasys (NASDAQ: FEMY) anuncia una asociación con HRC Fertility, un importante proveedor de servicios de fertilidad en la parte occidental de los EE. UU., para ofrecer el tratamiento de Inseminación Intratubal FemaSeed en localidades de California. FemaSeed es un tratamiento de fertilidad de primera línea que entrega esperma directamente en la trompa de Falopio, mostrando mayor eficacia en comparación con la inseminación intrauterina tradicional para recuentos bajos de espermatozoides masculinos. El tratamiento ofrece una opción rentable antes de considerar los procedimientos de FIV e ICSI.
Femasys (NASDAQ: FEMY)는 서부 미국의 주요 불임 서비스 제공업체인 HRC Fertility와 파트너십을 체결하고 캘리포니아 지역에서 FemaSeed 자궁관 내 인세미네이션 치료를 제공한다고 발표했습니다. FemaSeed는 남성 정자 수가 낮을 때 전통적인 자궁 내 인세미네이션에 비해 더 높은 효능을 보이는 초기 불임 치료입니다. 이 치료는 IVF 및 ICSI 절차를 진행하기 전에 비용 효율적인 옵션을 제공합니다.
Femasys (NASDAQ: FEMY) annonce un partenariat avec HRC Fertility, un fournisseur de services de fertilité majeur dans l'ouest des États-Unis, pour offrir le traitement d'Insemination Intratubaire FemaSeed dans des établissements en Californie. FemaSeed est un traitement de fertilité de première ligne qui délivre les spermatozoïdes directement dans la trompe de Fallope, montrant une efficacité supérieure par rapport à l'insémination intra-utérine traditionnelle en cas de faible nombre de spermatozoïdes masculins. Ce traitement offre une option économique avant d'envisager des procédures de FIV et d'ICSI.
Femasys (NASDAQ: FEMY) kündigt eine Partnerschaft mit HRC Fertility an, einem großen Anbieter von Fertilitätsdiensten im Westen der USA, um die FemaSeed intratubare Inseminationstherapie an Standorten in Kalifornien anzubieten. FemaSeed ist eine erstklassige Fertilitätsbehandlung, die Spermien direkt in den Eileiter abgibt und eine höhere Wirksamkeit im Vergleich zur herkömmlichen intrauterinen Insemination bei niedrigem männlichem Spermienanteil zeigt. Die Behandlung bietet eine kosteneffiziente Option, bevor IVF- und ICSI-Verfahren in Betracht gezogen werden.
- Partnership with major fertility provider HRC Fertility expands market reach in California
- FemaSeed demonstrates significantly higher efficacy compared to traditional intrauterine insemination
- Cost-effective treatment option positions product favorably in fertility market
- None.
Insights
This partnership represents a significant commercial milestone for Femasys, marking their expansion into the important California fertility market through HRC Fertility, a major player in Western U.S. fertility services. FemaSeed offers compelling advantages over traditional intrauterine insemination (IUI), particularly for cases involving low sperm count, while being more cost-effective than IVF treatments.
The collaboration with HRC Fertility, which operates multiple centers across California, creates substantial revenue potential for Femasys. The market validation from a prestigious fertility provider could accelerate broader adoption and additional partnerships. For a small-cap company with a
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California
ATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces a partnership with HRC Fertility, one of the largest and most established providers of IVF and fertility services in the Western U.S. HRC Fertility will provide the Company’s FemaSeed Intratubal Insemination as an infertility treatment option to patients at its California locations.
“HRC Fertility’s endorsement underscores the recognition of FemaSeed’s value, as an efficacious and accessible first-line option for patients. We are thrilled to bring our next generation technology to patients in California through HRC Fertility, a world class IVF and fertility care provider. We look forward to expanding the availability of FemaSeed through additional partnerships to bring this vital first-line fertility treatment solution to women,” said Femasys CEO Kathy Lee-Sepsick.
FemaSeed delivers sperm directly and safely into the fallopian tube where conception occurs. It is intended to enhance natural fertilization and provide a first-line treatment option for those seeking pregnancy through artificial insemination. When compared to other reproductive technologies, FemaSeed demonstrated significantly higher efficacy as compared to historic intrauterine insemination for low male sperm count and is a safe, highly cost-effective option prior to in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Dr. Bradford Kolb, President of HRC Fertility commented, “As a recognized leader in fertility services, HRC Fertility is constantly striving to advance our services and offer the latest innovations to our patients. FemaSeed is a progressive solution for the front end of care that will be a valuable addition to our suite of options, demonstrating our commitment to offer patients choices as they embark or continue their journey to parenthood.”
About FemaSeed
FemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It is intended to be a first-line therapeutic choice for infertile women, men, and couples seeking pregnancy through insemination, offering a safe, accessible, and cost-effective approach. FemaSeed is a revolutionary device that allows for the expansion of practice services by enabling healthcare professionals with a more affordable and safer alternative to assisted reproductive methods, such as in vitro fertilization (IVF). FemaSeed received U.S. FDA clearance (September 2023), regulatory approval in Canada (April 2023) and CE mark for Europe (June 2024). At the end of 2023, Femasys concluded a prospective, multi-center, pivotal clinical trial (NCT0468847) for those seeking intratubal insemination with FemaSeed. Positive data was published demonstrating FemaSeed as a safe and effective treatment option to achieve pregnancy in couples with male-factor/ unexplained infertility and low male sperm count.1 Learn more at www.femaseed.com.
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About HRC Fertility
HRC Fertility is one of the most established providers of advanced IVF and fertility care, boasting locations across Los Angeles, Orange, San Bernardino, and San Diego counties, with its San Francisco/Bay Area sites opening soon. Welcoming individuals, couples, and families from all walks of life, HRC Fertility is dedicated to helping its patients expand or build their families or preserve their family planning options for the future. The company was also recognized on Newsweek’s America’s Best Fertility Clinics 2023 list and the 2024 Healthcare Leadership Awards by the Los Angeles Business Journal. For detailed information about HRC Fertility’s services, locations, and providers, please visit www.HavingBabies.com
Reference
1 Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, K. Lee-Sepsick (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media Contact:
Kati Waldenburg
Media@femasys.com
FAQ
What is the new partnership announced by Femasys (FEMY) in December 2023?
How does FemaSeed treatment compare to traditional fertility treatments?
Where will FemaSeed treatment be available through the new Femasys (FEMY) partnership?
